DocGo Rejects Short Seller Report And Releases Preliminary 2024 Revenue Guidance; Sees FY23 Revenue $615M-$625M Vs $619.24M Est.; FY24 Revenue To Exceed $700M Vs $760.2M Est.
Portfolio Pulse from Benzinga Newsdesk
DocGo Inc. has publicly dismissed a negative report by Fuzzy Panda Research, calling it false and defamatory. The company reaffirms its FY23 revenue guidance of $615M-$625M, aligning with estimates, and projects FY24 revenue to exceed $700M, contrary to the short seller's claims of decline. DocGo emphasizes its growth, compliance with billing practices, and inaccuracies in the report regarding liabilities and contract expirations.
January 10, 2024 | 9:02 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
DocGo Inc. refutes Fuzzy Panda Research's negative report, maintains FY23 revenue guidance of $615M-$625M, and anticipates FY24 revenue to surpass $700M, which is a positive outlook for the company's financial performance.
The company's rejection of the short seller report and reaffirmation of its revenue guidance is likely to instill investor confidence and could positively impact the stock price in the short term. The specific mention of expected revenue growth for FY24, despite the short seller's claims, further supports a positive outlook.
CONFIDENCE 85
IMPORTANCE 90
RELEVANCE 100